These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 21471647

  • 1. Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer's disease: results of a 16-week open-label trial.
    Schulz JB, Rainer M, Klünemann HH, Kurz A, Wolf S, Sternberg K, Tennigkeit F.
    J Alzheimers Dis; 2011; 25(3):463-75. PubMed ID: 21471647
    [Abstract] [Full Text] [Related]

  • 2. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
    Mecocci P, Bladström A, Stender K.
    Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640
    [Abstract] [Full Text] [Related]

  • 3. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
    Riepe MW, Adler G, Ibach B, Weinkauf B, Tracik F, Gunay I.
    Dement Geriatr Cogn Disord; 2007 May; 23(5):301-6. PubMed ID: 17356273
    [Abstract] [Full Text] [Related]

  • 4. Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer's disease.
    Weiner MW, Sadowsky C, Saxton J, Hofbauer RK, Graham SM, Yu SY, Li S, Hsu HA, Suhy J, Fridman M, Perhach JL.
    Alzheimers Dement; 2011 Jul; 7(4):425-35. PubMed ID: 21646051
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Memantine and functional communication in Alzheimer's disease: results of a 12-week, international, randomized clinical trial.
    Saxton J, Hofbauer RK, Woodward M, Gilchrist NL, Potocnik F, Hsu HA, Miller ML, Pejović V, Graham SM, Perhach JL.
    J Alzheimers Dis; 2012 Jul; 28(1):109-18. PubMed ID: 21955815
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
    Aupperle PM, Koumaras B, Chen M, Rabinowicz A, Mirski D.
    Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.
    Pomara N, Ott BR, Peskind E, Resnick EM.
    Alzheimer Dis Assoc Disord; 2007 Oct; 21(1):60-4. PubMed ID: 17334274
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
    Wilkinson D, Andersen HF.
    Dement Geriatr Cogn Disord; 2007 Oct; 24(2):138-45. PubMed ID: 17622761
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease.
    Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ.
    Arch Neurol; 2006 Jan; 63(1):49-54. PubMed ID: 16401736
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.